Navigation Links
KAHR Medical, a Hadasit Bio-Holdings Portfolio Company, to Raise $2.5M
Date:9/11/2013

JERUSALEM, Sept. 11, 2013 /PRNewswire/ -- Hadasit Bio-Holdings (TASE: HDST, OTC: HADSY) a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by the Hadassah University Hospital, today announced that KAHR Medical Ltd. ("KAHR"), a portfolio company in which Hadasit Bio hold approximately 55%, will raise $2.5M at a valuation of $13.5M pre-money. Of the investment, $1.65M will be invested by Flerie Invest AB, a company controlled by Thomas Eldered, co-owner of Recipharm (www.recipharm.com), one of the largest pharmaceutical Contract Development and Manufacturing Organizations (CDMO) in Europe.  Sanofi, the third largest pharmaceutical company in the world, will maintain its current holdings with an investment of $500K and Hadasit Bio will invest an additional $200K. An additional $150K will be offered as a one year option to Flerie and Hadasit Bio.

Dr. Rafi Hofstein, Chairman of Hadasit Bio-Holdings: "We are happy to announce the closing of this important financing for KAHR. This funding will allow the company to advance its lead product into a Phase I trial – thus proving the groundbreaking science and technology within a controlled clinical setting. We are proud of the strong partnerships the company has established with Sanofi and Flerie and look forward to working together in order to move this promising drug platform towards commercialization."

Dr. Noam Shani, CEO of KAHR: "We are especially excited about this investment because we are planning a first-in-men clinical trial with KAHR-102 in Lymphoma patients and this investment should allow its completion. The partnerships we have formed with major strategic partners such as Mr. Eldered, co-founder and CEO of one of the leading pharmaceutical CDMOs in Europe, and with Sanofi, the third largest global pharmaceutical company, have already proven to be one of our greatest assets. We are now positioned towards the clinical stage of development."

Following the investment, Sanofi, Flerie Invest AB and Hadasit Bio will hold approximately 20%, 24% and 48% of KAHR shares, respectively.

KAHR Medical is developing a technology platform known as SCP (Signal Converter Proteins), which allows the construction of protein-based drugs with two functional sides. In contrast to current biological drugs that possess only one functional side, the two functional sides of SCPs allow these drugs to block or activate two reinforcing biological signals at the same time. The SCP platform forms a new generation of biological drugs with great diversity and superior efficacy.

KAHR's leading products, KAHR-101 and KAHR-102, are in pre-clinical development towards treatment of several cancers and autoimmune diseases and are expected to enter clinical trials next year.

About KAHR Medical:

KAHR develops novel drugs that are based on the SCP (Signal Converter Proteins) platform technology for the treatment of cancer and autoimmune diseases. The company's technology is based on many years of research by Dr. Michal Dranitzki Elhalel, Head of Nephrology and a senior researcher at the Hadassah Medical Center, and Professor Mark Tykocinski, Dean of the School of Medicine at Jefferson University in Philadelphia and former Chief of Pathology at the University of Pennsylvania. KAHR Medical is managed by Dr. Noam Shani.

For more information please visit - www.kahr-medical.com

About Hadasit Bio-Holdings:

Hadasit Bio-Holdings, Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital, Israel's foremost medical research center. The Company was established for the purpose of promoting and commercializing the intellectual property and R&D capabilities generated by Hadassah.

HADSY is the domestically traded ADR of Hadasit Bio-Holdings, a public investment vehicle of six portfolio biotech companies all based on inventions developed by Hadassah.  Hadasit Bio-Holdings focuses on advancing companies that have already shown proof of concept and successful preclinical trials to completion of Phase I/II.

The portfolio companies develop drugs with blockbuster potential (targeting markets that are worth over a billion dollars) operating in the fields of cancer, inflammatory diseases and tissue regeneration using stem cells - areas in which the Hadassah Hospital has extensive knowledge and recognition as a global leader.

For more information please visit:  www.hbl.co.il

Investor Contact
KCSA Strategic Communications
Phil Carlson / Josh Dver
212-896-1233 / 212-896-1239
pcarlson@kcsa.com / jdver@kcsa.com

 


'/>"/>
SOURCE Hadasit Bio-Holdings
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission
2. Astute Medical, Inc. va Accueillir le Symposium portant sur linsuffisance rénale du 33e ISICEM annuel
3. Astute Medical, INC. ist Veranstalter eines SYMPOSIUMS zu Nierenerkrankungen beim 33. jährlichen ISICEM
4. Astute Medical, Inc. organizará el 33. simposio anual en el congreso ISICEM sobre daño renal
5. Astute Medical, Inc. ospiterà il simposio sullinsufficienza renale al 33o incontro annuale ISICEM
6. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
7. Astute Medical, Inc. promuove lultima generazione di biomarcatori per lesioni renali acute
8. Astute Medical, Inc. Advancing Next Generation Acute Kidney Injury Biomarkers
9. Saladax Biomedical, Inc. Announces the Formation of a CLIA Laboratory As Part of the Companys Commercialization Strategy
10. KAHR Medical, a Hadasit Bio-Holdings Portfolio Company, to Raise $2.6 Million
11. MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Overall Category in Medical, Dental & Related Services/Trade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) today announced that its ... $250 million of the company,s common stock. This program ... December 31, 2017. Purchases may be made in the ... transactions from time to time as determined by United ...
(Date:4/27/2017)... ... April 27, 2017 , ... Arrowhead ... ( http://www.paintherapeuticsummit.com ) is coming to San Diego, CA on September 27-28, 2017. ... learn about the latest advances in the treatment of various types of pain. ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... 2017 Borlaug CAST Communication Award goes to Jayson Lusk, a consummate communicator who ... of media to advocate for science, as he explains how innovation and growth ...
(Date:4/26/2017)... USA (PRWEB) , ... April 26, 2017 , ... ... on FDA’s GMP expectations for phase I clinical trials comes to Tampa, San ... various biotechnology and pharma professionals representing FDA regulated organizations such as Pfizer Inc., ...
Breaking Biology Technology:
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
(Date:3/16/2017)... Germany , March 16, 2017 CeBIT 2017 - Against identity ... Continue Reading ... Used combined in one project, multi-biometric solutions provide ... Used ... Systems) ...
Breaking Biology News(10 mins):